1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: What impact has the controversy surrounding use of testosterone products had on urologists?

Physician Views: What impact has the controversy surrounding use of testosterone products had on urologists?

  • August 2014
  • ID: 2343489
  • Format: PDF
  • Firstword Pharma

Summary






The number of prescription written for testosterone replacement therapy has skyrocketed over the past couple decades thanks in no small measure to a concerted effort on the part of a handful of drugmakers to heighten awareness of hypogonadism – or "Low T" as it is often referred to – through direct-to-consumer campaigns.


It should be noted that advertising alone is not the only driving force behind the significant increase in use of testosterone products, as data released recently by the Massachusetts Male Aging Study suggest that almost 2.5 million men ages 40 to 69 suffer from hypogonadism, with just under 500 000 new cases emerging each year.


Questions have long been asked about whether and at what level of endogenous testosterone production does "Low T" become a condition requiring treatment. More recently, however, the debate about the potential benefits of testosterone therapy took on a new urgency after a published study late last year pointed to links between use of the products and an increased risk of cardiovascular events.


Sales of testosterone products from companies including AbbVie and Eli Lilly topped $2 billion in 2012 and, at the time, analysts were still predicting rapid growth of the market.


More recently, the FDA said in June that all testosterone-based therapies should carry warnings of a risk of blood clots, while also scheduling an advisory panel meeting to evaluate the adverse cardiovascular effects of testosterone replacement therapies that will take place on September 17.


Indeed, lingering questions about potential overuse of the products and, perhaps more importantly, concern about possible safety risks appear to have begun taking a toll on the growth prospects.









Thus, to better understand how the marketplace for testosterone replacement therapies is evolving, FirstWord is this week polling US and EU5-based urologists. Specifically we are asking them...


In your opinion, the number of patients being treated for "Low-T" (or hypogonadism) is too low or too high?
How has the number of men interested in receiving testosterone therapy changed over the past 8 to 12 months?
How has the controversy surrounding use of testosterone products (in particular the FDA's announcement that it would be launching an investigation into a possible cardiovascular safety signal) affected your prescribing patterns?
On a scale of 1 to 10, how concerned are you about the evidence available suggesting CV risks associated with testosterone products?
Marketed testosterone products are delivered transdermally or by injections. A new (still experimental) product – an oral pill containing an inactivated version of testosterone that becomes activated by enzymes in the body, thus being quicker, easier and avoiding the risk of transference to a woman or child – is in Phase IV trials. Given the various advantages (while also taking into account its similar pharmacological activity once activated), might you be any more/less likely to use this product versus the transdermal/injectable options?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

2021-2026 Database: US Clinical Chemistry Market--Supplier Shares, Volume and Sales Segment Forecasts for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein and TDM Tests

  • $ 2850
  • December 2021
  • 1 pages

2021-2026 Database: US Clinical Chemistry Market--Supplier Shares, Volume and Sales Segment Forecasts for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein and TDM Tests This unique report ...

  • United States
  • Clinical Chemistry
  • Anti-Infective
  • Industry analysis

ref:plp2014

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on